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OligoPVP: Phenotype-driven 
analysis of individual genomic 
information to prioritize oligogenic 
disease variants
Imane Boudellioua1, Maxat Kulmanov  1, Paul N. Schofield  2, Georgios V. Gkoutos3,4,5,6,7 & 
Robert Hoehndorf  1
An increasing number of disorders have been identified for which two or more distinct alleles in two 
or more genes are required to either cause the disease or to significantly modify its onset, severity or 
phenotype. It is difficult to discover such interactions using existing approaches. The purpose of our 
work is to develop and evaluate a system that can identify combinations of alleles underlying digenic 
and oligogenic diseases in individual whole exome or whole genome sequences. Information that 
links patient phenotypes to databases of gene–phenotype associations observed in clinical or non-
human model organism research can provide useful information and improve variant prioritization 
for genetic diseases. Additional background knowledge about interactions between genes can be 
utilized to identify sets of variants in different genes in the same individual which may then contribute 
to the overall disease phenotype. We have developed OligoPVP, an algorithm that can be used to 
prioritize causative combinations of variants in digenic and oligogenic diseases, using whole exome or 
whole genome sequences together with patient phenotypes as input. We demonstrate that OligoPVP 
has significantly improved performance when compared to state of the art pathogenicity detection 
methods in the case of digenic diseases. Our results show that OligoPVP can efficiently prioritize sets 
of variants in digenic diseases using a phenotype-driven approach and identify etiologically important 
variants in whole genomes. OligoPVP naturally extends to oligogenic disease involving interactions 
between variants in two or more genes. It can be applied to the identification of multiple interacting 
candidate variants contributing to phenotype, where the action of modifier genes is suspected from 
pedigree analysis or failure of traditional causative variant identification.
Discrimination of causative genetic variants responsible for disease is a major challenge. An increasingly large 
family of algorithms and strategies has been developed to aid in identification of such variants1. These methods 
use properties of variants such as evolutionary conservation, predicted structural changes, allele frequency and 
function to predict pathogenicity. For variants in non-coding sequence regions, additional information used by 
computational models includes predicted regulatory function and recognized DNA–protein or DNA–RNA inter-
actions1–3. Furthermore, phenotype annotations to human and model organism genes can be added to provide 
another layer of discrimination between involved pathogenic and non-pathogenic variants4–6. Phenotype-based 
methods can identify the likelihood that a particular gene or gene product may give rise to phenotypes observed 
in an individual7,8.
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The increasing availability of patient sequence information coupled with resources that provide a detailed 
phenotypic characterization of diseases, as well as the wealth of gene-to-phenotype associations from non-human 
disease models9, are now enabling new approaches to the prioritization of causative variants and facilitating our 
ability to dissect the genetic underpinnings of disease5. PhenomeNET10, developed in 2011, is a computational 
framework that utilizes pan-phenomic data from human and non-human model organisms to prioritize candi-
date genes in genetically-based diseases10. We have combined PhenomeNET with genome-wide pathogenicity 
predictions to develop the PhenomeNET Variant Predictor (PVP)4 as a system that combines information about 
pathogenicity of variants with known gene–phenotype associations to predict causative variants. We recently 
developed the PVP system to classify variants into those likely to be causative or non-causative4.
While PVP has a significantly better performance in the prioritization of single variants in monogenic diseases 
than competing algorithms4, the phenotypes of many diseases with a recognized genetic origin show a range of 
severity, phenotypic spectrum, age of onset and prognosis11. While characteristic phenotypic variability can be 
associated with different alleles in single disease-causing genes or their mode of inheritance, it has been known 
for some time that in many diseases there is variable expressivity, and in some cases variable penetrance, asso-
ciated with the same primary mutation in different individuals or pedigrees12. This implies that in those cases 
the phenotypic variability observed must be due to the presence of other modifier variants or environmental 
influences. Increasingly, several diseases are being understood within the context of complex inheritance and 
multifactorial disease phenotypes where multiple independent variants modify each other’s effect on phenotype13, 
or, in some cases, render the disease di- or oligogenic where variants in two or more different genes are needed for 
its clinical manifestation14. Evidence for digenic inheritance is available for around 50 diseases15 and details are 
gathered in the Digenic disease database (DIDA)16.
Epistatic interactions have been postulated to explain the missing heritability in many types of common and 
rare disease12, and with the increasing clinical use of next generation sequencing, further evidence is accumulat-
ing for a spectrum of types of interactions between genes. These interactions are manifest in different ways. For 
example, there is evidence from population genetics for phenotypic modifier genes such as the modifiers of the 
age of onset in Huntington’s disease17,18, and from a candidate gene approach in Parkinson’s disease19. In a similar 
candidate approach for amyotrophic lateral sclerosis (ALS), affected individuals with proven or potentially path-
ogenic mutations in two or three known ALS genes are associated again with lower age of disease onset.
Congenital hypothyroidism has both rare monogenic recessive loss-of-function, and common, apparently 
sporadic, forms. The recent description of patients carrying biallelic and triallelic digenic combinations of var-
iants in known thyroid development and function genes20 has lead to the suggestion that a frequent oligogenic 
origin might explain sporadic hypothyroid cases. Evidence has also been provided for rare trigenic involvement 
of variants, such as in TSHR, SLC26A4 and GLIS321. In addition to these examples of genetic interaction, the 
observations suggesting digenic/triallelic inheritance in Bardet-Biedel syndrome (BBS)22 continue to provoke 
interest and further research, and illustrate the challenges in establishing formal digenicity23. One of the best 
characterized cases of digenic inheritance is a form of Usher syndrome where digenic heterozygous mutations 
in CDH23 and PCDH15 have been shown to interact in both humans and mice24. Other examples are critically 
discussed elsewhere15.
Digenic disease can be divided into two classes: strict digenic disease where variants at both loci are required 
for the disease, and composite disease which is either the result of the epistatic relationship between alleles of two 
independent genes modifying the phenotypes of the individual mutations alone, or the phenotypic overlay of two 
monogenic Mendelian diseases present in the same patient25,26. Identification of the genes involved in all of these 
types of digenic disease usually requires pedigree information or the use of existing knowledge about candidate 
genes. For example, the selection of candidate genes may rely on the availability of additional information about 
molecular or functional connections between the entities (genes or gene products) bearing the variants20. The 
difficulties in establishing strong evidence for digenic inheritance are discussed elsewhere15,27.
Computational identification of likely causative alleles that are involved in digenic or genetically more com-
plex diseases, in particular for genes not previously associated with the disease, is particularly challenging; such 
methods would have to be able to incorporate and utilize a large amount of background information about 
molecular and (patho-)physiological interactions within an organism to determine how combinations of variants 
jointly result in an observed phenotype. The observation that disease-implicated proteins often interact with each 
other has stimulated the development of network-based approaches to identification of disease modules28–31. 
However, relevant interactions may occur across much larger distances within pathways and networks, or at the 
whole organism physiological level where knowledge about biological systems and multi-scale interactions is 
critical for understanding pathobiology32,33. Phenotypes provide a readout for all of these disease-relevant inter-
actions and offer insights into the underlying pathobiological mechanisms34. Phenotype data can be a powerful 
source of information for variant prioritization and is complementary to pathogenicity prediction methods based 
on molecular information4,35–38.
Here, we first evaluate the ability of the PVP system to identify combinations of variants in digenic diseases 
obtained from a database of digenic diseases. We then present OligoPVP, a novel algorithm for prioritizing 
digenic or higher order combinations of variants in personal genomes. While the OligoPVP algorithm will not 
identify whether a phenotype or disease has a digenic or oligogenic inheritance, it identifies and ranks potential 
causative variants in the same way as PVP but then prioritizes pairs or sets of higher cardinality of potentially 
interacting variants present in the same genome, as specified by the user, on the basis of prior knowledge about 
genetic, regulatory and biochemical interactions between them. It is therefore mainly useful to identify candidate 
causative sets of variants in cases in which digenic or oligogenic inheritance is already suspected, for example due 
to variable penetrance or expressivity in family studies, or as means of exclusion because established methods for 
variant prioritization failed.
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We apply OligoPVP to the identification of variants in pairs of genes where mutations in two separate genes 
present in a single individual and lead to a particular phenotypic profile that is not apparent in individuals car-
rying only one of these variants. We demonstrate that OligoPVP is able to identify gene variant sets in digenic 
diseases using a set of synthetic whole genome sequences into which we insert multiple known causative gene 
variants. OligoPVP is freely available at https://github.com/bio-ontology-research-group/phenomenet-vp.
Materials and Methods
Digenic disease. The Digenic Disease Database (DIDA) v216 consists of 258 curated digenic combinations 
representing 54 diseases, with 448 variants in 169 genes. Of the 258 digenic combinations, 189 have Human 
Phenotype Ontology (HPO) annotations, representing 52 diseases, 153 distinct genes, and 337 unique variants. 
We use the 189 digenic combinations with HPO annotations in our experiments. 25 of these combinations are 
triallelic and exhibit compound heterozygosity in one gene while the remaining 164 combinations are biallelic.
We use the combinations of variants from DIDA to generate 189 synthetic whole genome sequences by ran-
domly inserting the causative variants in a randomly selected whole genome sequence from the 1000 Genomes 
Project39.
Interaction data. We downloaded all interactions occurring in humans from the STRING database version 
10.540. Then, we mapped all interactions to their respective genes using the mapping file provided by STRING to 
generate 989,998 interactions between genes, representing 13,770 unique genes. We use these interactions 
between genes to prioritize combinations of variants in OligoPVP.
PhenomeNET Variant Predictor. In our work, we use the PhenomeNET Variant Predictor (PVP) ver-
sion 2.0 (“DeepPVP”)41. This version of PVP is based on the Human Phenotype Ontology (HPO)35 and the 
Mammalian Phenotype Ontology (MP)42 ontologies obtained from the AberOWL repository43 on Feb 7th, 2017. 
PVP uses gene-to-phenotype associations in humans as well as from the mouse and zebrafish model organ-
isms downloaded on Feb 7th, 2017 from the HPO website35, the Mouse Genome Informatics website42, and the 
Zebrafish Information Network website44, respectively. The PVP system was trained on data generated from the 
ClinVar database45 accessed on Feb 7th, 2017.
PVP combines features that score the pathogenicity of variants with a phenotype similarity measure that aims 
to identify whether a variant is likely to cause the phenotypes observed in a patient. Using the cross-species phe-
notype ontology PhenomeNET46, phenotype similarity also can be computed between patient phenotypes and 
phenotypes in model organisms.
The PVP system used in our analysis, the synthetic genome sequences we generated for the evaluation 
of our system, and our analysis results can be found at https://github.com/bio-ontology-research-group/
phenomenet-vp.
Evaluation and comparison. We compare PVP and OligoPVP to several state of the art variant prioritiza-
tion method. Specifically, we compare the PVP and OligoPVP scores to variant pathogenicity prediction scores 
obtained from CADD v1.347, DANN v1.048, and GWAVA v1.049. Furthermore, we compare our results to the 
phenotype-based tool Genomiser version 7.2.150 using its default parameters.
Results
Prediction of biallelic and triallelic disease variants. We analyze each WGS using the phenotypes 
provided for the combination of variants in DIDA. We do not filter any variants by minor allele frequency to 
avoid missing potentially important interacting variants that might have medium to common frequencies in the 
background population. On average, each WGS in our experiments contains 2,192,967 variants.
We use the phenotypes associated with the combination of variants in DIDA as phenotypes associated with 
the synthetic WGS, and we use PVP4 to prioritize variants, using an “unknown” mode of inheritance model. 
Out of 164 whole genome sequences where two variants were inserted, we find both causative variants (i.e., the 
two variants we inserted) as the highest ranked variants in 88 cases (53.7%) and within the top ten ranks in 107 
cases (65.2%) (see Table 1). For the 25 cases of triallelic diseases, we find all three causative variants within the 
first three ranks in 10 cases (40.0%) and we find all three causative variants within the top ten variants in 14 cases 
(56.0%) (see Table 2). Tables 1 and 2 also compare PVP to established variant prioritization methods, including 
All Interacting only
Top pair
Top 10 
pairs Combinations Top pair
Top 10 
pairs
Interacting 
combinations
PVP 88 (53.7%) 107 (65.2%) 164 42 (59.2%) 51 (71.8%) 71
CADD 34 (20.7%) 87 (53.1%) 164 10 (14.1%) 37 (52.1%) 71
DANN 5 (3.1%) 59 (36.0%) 164 0 17 (23.9%) 71
Genomiser 0 0 164 0 0 71
GWAVA 0 0 164 0 0 71
OligoPVP 47 (28.7%) 59 (36.0%) 164 47 (66.2%) 59 (83.1%) 71
Table 1. Comparison of different variant prioritization systems for recovering biallelic variants. We split the 
evaluation in two parts, one in which we consider all variants and another in which we only consider variants 
for which we have background knowledge about their interactions.
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CADD47, DANN48, the phenotype-based Exomiser/Genomiser system50, and GWAVA49. Out of these systems, 
CADD performs the best in prioritizing combinations of variants; however, PVP can rank variant involved in bi- 
or triallelic diseases significantly higher than CADD (Mann-Whitney U test, p = 6.8 × 10−5).
Individually, the performance of our approach differs between diseases, depending on the availability of gene–
phenotype associations and high quality and informative disease–phenotype associations in DIDA. Table 3 pro-
vides an overview of the performance of PVP for individual diseases, and we provide the full analysis results on 
our website.
In particular, for the case of hypodontia, PVP identifies all the causative variant pairs in the top 3 ranks in all 
synthetic patients, and in Familial long QT syndrome, the causitive variant pairs can be found in the top 3 ranks 
in over 90% of the synthetic patients. Similarly, for the case of Bardet-Biedl syndrome (BBS), PVP ranks 84.21% 
of causative variant pairs in the top 10, and identifies digenic causative variants in 9 of the 16–20 genes now 
implicated in BBS23,51.
To ensure that newer versions of ontologies and our training data do not already contain, implicitly, informa-
tion about associations between variants and disease, we perform a semi-prospective experiment; the PVP system 
we used is based on ontology versions (HPO and MP) and training data obtained on Feb 7th, 2017. We separately 
test the performance of our system on the digenic cases added to the DIDA database after Feb 7th, 2017. In total, 
45 digenic combinations with HPO annotations are newly added to DIDA after the date our PVP system was 
built. Among these newly added combinations, 42 are biallelic and 3 are triallelic. Table 4 shows the performance 
of PVP on these cases. We find that the performance on predicting the new cases drops somewhat in comparison 
to cases before the PVP build date.
All Interacting only
Top triple
Top 10 
triple Combinations Top triple
Top 10 
triple
Interacting 
combinations
PVP 10 (40.0%) 14 (56.0%) 25 7 (43.8%) 10 (40.0%) 16
CADD 4 (16.0%) 9 (36.0%) 25 7 (43.8%) 12 (75.0%) 16
DANN 0 6 (24.0%) 25 0 4 (25.0%) 16
Genomiser 0 0 25 0 0 16
GWAVA 0 0 25 0 0 16
OligoPVP 10 (40.0%) 10 (40.0%) 25 10 (62.5%) 10 (62.5%) 16
Table 2. Comparison of different variant prioritization systems for recovering triallelic variants. We split the 
evaluation in two parts, one in which we consider all variants and another in which we only consider variants 
for which we have background knowledge about their interactions.
Top hit Top 3 hits Top 10 hits
Variants 
(Combinations)
Familial long QT syndrome 21 (50.0%) 38 (90.5%) 41 (97.6%) 42 (21)
Kallmann syndrome 18 (47.4%) 27 (71.1%) 27 (71.1%) 38 (19)
Bardet-Biedl syndrome 14 (36.8%) 28 (73.7%) 32 (84.2%) 38 (14)
Alport syndrome 14 (45.2%) 28 (90.3%) 29 (93.6%) 31 (15)
Non-syndromic genetic deafness 12 (50.0%) 18 (75.0%) 18 (75.0%) 24 (12)
Oculocutaneous albinism 6 (40.0%) 12 (80.0%) 12 (80.0%) 15 (7)
Primary ovarian insufficiency 2 (13.3%) 2 (13.3%) 2 (13.3%) 15 (7)
Usher syndrome 5 (33.3%) 11 (73.3%) 12 (80.0%) 15 (7)
Hypodontia 6 (50.0%) 12 (100.0%) 12 (100.0%) 12 (6)
Others 66 (38.2%) 118 (68.2%) 128 (74.0%) 173 (81)
Table 3. Analysis of top ranks of variants by PVP summarized by disease.
Biallelic Triallelic
Top pair
Top 10 
pairs Combinations Top triple
Top 10 
triples
Interacting 
combinations
All DIDA 88 (53.7%) 107 (65.2%) 164 10 (40.0%) 14 (56.0%) 25
Old DIDA 69 (56.6%) 84 (86.9%) 122 10 (45.5%) 14 (63.6%) 22
New DIDA 19 (45.2%) 23 (54.8%) 42 0 0 3
Table 4. Performance of PVP on all combinations present in DIDA database (All DIDA), combinations added 
before the PVP build date date of Feb 7th, 2017 (Old DIDA), and combinations added after the cutoff date of 
Feb 7th, 2017 (New DIDA).
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OligoPVP: Use of background knowledge to find causative combinations of variants. Our 
results demonstrate that PVP can identify combinations of variants implicated in a disease, outperforming cur-
rent state-of-the-art gene prioritization approaches. The variants found by PVP are commonly in genes that form 
a disease module, i.e., a set of interacting genes that are jointly associated with a disease or phenotype52. For 
example, out of the 164 biallelic combinations used in our study, we can find evidence of interactions for 71 
biallelic combinations and 16 triallelic combinations using the interaction database STRING40. The STRING 
resource contains background knowledge about the interaction between genes based on protein-protein inter-
actions, co-expression, pathway involvement, or co-mention in literature, and therefore provides a wide range of 
distinct interaction types which may underlie a phenotype. We have now exploited this background knowledge 
to further improve prioritization of variants in oligogenic diseases which involve interactions between alleles of 
two or more genes.
OligoPVP is an algorithm that uses background knowledge from interaction networks to prioritize variants in 
oligogenic diseases. It identifies likely causative variants in interacting genes and ranks tuples of n variants in 
genes that are connected through an interaction network. OligoPVP will first rank all variants in a set of variants 
(such as those found in a VCF file) independently using PVP and assign each variant ν a prediction score σ(ν). 
When ranking combinations of n variants, OligoPVP will then evaluate all n-tuples of variants ...v v, , n1  and 
assign a score σ to the n-tuple ...v v( , , )n1 , given an interaction network ϒ:
σ σ σ... =




+ ... + ... ϒv v v v v v
otherwise
( , , ) ( ) ( ) if , , are variants in a connected subgraph of
0n
n n
1
1 1
Algorithm 1 illustrates the procedure to find oligogenic disease modules in more detail. OligoPVP can identify 
combinations of variants both in exonic and non-exonic regions. For non-exonic variants, we assign the gene that 
is located closest to the variant as the variant’s gene.
The OligoPVP algorithm strictly relies on an interaction network as background knowledge and will not 
prioritize any combinations of variants if they are not connected in a known network. For digenic or oligogenic 
disease we assume that the interactions between alleles are mediated directly or indirectly through physical or 
Algorithm 1. OligoPVP prioritization of oligogenic combinations.
DIDA ID Gene A Gene B Disease name (ORPHANET)
PVP 
Rank A
PVP 
Rank B
OligoPVP 
Rank
dd225 PSMA3 (c.696_698delAAG) PSMB8 (c.224C > T) CANDLE syndrome 8 1 1
dd226 PSMA3 (c.404 + 2T > G) PSMB8 (c.224C > T) CANDLE syndrome 292 1 2
dd228 PSMB4 (c.666C > A) PSMB8 (c.313A > C) CANDLE syndrome 1980 1 2
dd159 EMD (c.110_112delAGA) LMNA (c.892C > T) Familial atrial fibrillation 1 21 4
dd043 SCN1A (c.5054C > T) SCN2A (c.1571G > A) Generalized epilepsy with febrile seizures-plus 1 7 2
dd114 CD2AP (c.1488G > A) NPHS2 (c.622G > A) Familial idiopathic steroid-resistant nephrotic syndrome 1 141 4
dd053 KCNE1 (c.379C > A) KCNQ1 (c.1022C > T) Familial long QT syndrome 30 1 4
dd229 CDK5RAP2 (c.4187T > C) CEP152 (c.3014_3015delAAinsT) Seckel syndrome 22 1 5
dd007 PCDH15 (c.5601_5603delAAC) CDH23 (c.193delC) Usher syndrome 7 1 1
dd052 HAMP (c.212G > A) HFE (c.845G > A) Rare hereditary hemochromatosis 22 1 3
Table 5. Cases of DIDA combinations improved by OligoPVP in comparison to PVP. OligoPVP incorporates 
protein-protein interactions in the prioritization of variant tuples. We compare the results of applying OligoPVP 
to the ranks obtained using PVP on individual variants.
www.nature.com/scientificreports/
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regulatory mechanisms at any level, e.g., through DNA (for example transcriptional regulation), RNA (for exam-
ple processing of RNA or half life modulation), or protein (e.g., direct functional interaction or co-participation 
in the same pathway or physiological processes). Data relevant to all these levels of interaction is available in 
STRING. OligoPVP is of course limited by the completeness of the interaction data available and until more 
complete high level physiological modeling is achieved, interactions at the level of the whole organism physiome 
will be difficult to capture.
OligoPVP utilizes beam search53 to optimize memory usage. We can simply extend OligoPVP to also consider 
compound heterozygote combinations of variants by adding self-loops to each node in ϒ. The main advantage 
of OligoPVP is its ability to identify and rank connected sets of variants higher than individual variants. Table 5 
lists several cases in which OligoPVP prioritizes pairs of variants higher than PVP would prioritize them on their 
own. On the other hand, OligoPVP will not prioritize combinations of variants if they are in genes that are not 
connected in the background network ϒ. Supplementary Table 1 lists some of the cases which can be prioritized 
with PVP but not OligoPVP.
Discussion
With the increasing appreciation of the relationship between complex and Mendelian diseases54, the ability to 
discover multiple variants contributing to disease phenotype in the same genome provides a powerful tool to help 
understand the genetic architecture of diseases and the underlying physiological pathways. With the advent of 
whole exome and whole genome sequencing, advances have been made using existing approaches to prioritize 
causative variants. However, use of standard criteria for the identification of rare disease variants, e.g., a low 
minor allele frequency (MAF) of, for example, less than 1%, are designed to detect de novo, homozygous, or 
compound heterozygous variants, and may not give sufficient priority to variants of low apparent pathogenicity, 
haploinsufficiency, or low to medium MAF, although these variants may still be important in the pathogenesis of 
a disease. Because the approach we take with OligoPVP and PVP makes no assumptions about allele frequency or 
mode of inheritance, and balances estimates of pathogenicity with phenotypic relatedness, a wider net is cast and 
candidate genes affecting the penetrance, expressivity or spectrum of the phenotype are more readily identified.
Genes whose variants contribute to a disease phenotype are considered likely to be situated within the same 
pathway or network55–58. In addition to well established studies of genes involved in, for example the ciliopa-
thies23,59, newer studies are now identifying network relations between genes implicated in the oligogenic origins 
of diseases60,61. Consequently, we can exploit background knowledge on the interactions of gene products in 
OligoPVP and improve the ranking of candidate pairs of variants over that assigned through pathogenicity and 
phenotypic relatedness scores alone.
Currently, identification of multiple variants contributing to the characteristics of a disease in a cohort or indi-
vidual patient rely either on a candidate gene approach or the assumption that contributing alleles are likely to be 
rare in the population. The contribution of rare alleles of low effect, i.e., which by themselves generate sub-clinical 
phenotypes, for example hypomorphs, may be missed in this way, and rare to medium frequency alleles which mod-
ify the penetrance or expressivity of a second remain difficult to identify (the former because of low potential path-
ogenicity and the latter because of high frequency and lack of association with a phenotype when occurring alone). 
An alternative strategy for identification of candidate genes for highly heterogeneous human diseases is to use mouse 
genetics to identify phenotypic modifier genes. For example, neural tube defects are believed to involve more than 
300 genes in the mouse, mutations in many of which need to be digenic or trigenic for expression of the pheno-
type62. Similarly, mouse double heterozygous mutants in Nkx2-1 and Pax8 show strain-specific thyroid dysgenesis 
phenotypes not seen in the individual mutations63. The scale of genetic interactions becoming apparent from mouse 
studies strongly supports the suggestion that in the human, we are only seeing the tip of a very important iceberg64.
The OligoPVP algorithm offers a generic framework for using background knowledge about any form of 
interaction between genes and gene products to guide the identification of combinations of variants. In its generic 
form, the worst case complexity of the algorithm is  n( )k  where n is the number of variants and k the size of the 
module (the size of the module is a parameter of OligoPVP). It is clear that our algorithm, in its basic form, will 
not yet scale to large disease modules (i.e., large k); however, in the future, several methods can be used to further 
improve the average case complexity to find larger disease modules.
Furthermore, background knowledge about interactions between genes and gene products is far from com-
plete. In particular, information about coarse scale physiological interactions, i.e., those that occur based on 
whole organism physiology, are significantly underrepresented in interaction databases32. Additionally, interac-
tion networks may have biases such as over-representation of commonly studied genes65,66, and these biases will 
likely effect the performance of our algorithm. As more genomic data related to complex diseases becomes avail-
able, more work will be required to identify and remove these biases in the identification of phenotype modules 
from personal genomic data.
The function of OligoPVP is not to determine whether a disease is formally di- or oligogenic but to assess 
whether sets of variants may be jointly responsible for phenotype when an individual contains multiple, poten-
tially pathogenic, variants in two or more genes that might, from background knowledge, be expected to interact 
to generate the phenotypic profile of the patient. The user is able to specify the cardinality of the set of variants 
that should be prioritized, and the rank scores provide a relative measure of the likelihood that two, three or more 
specific allelic variants might be involved.
While this limitation restricts OligoPVP’s applicability, we nevertheless believe our algorithm to have impor-
tant applications. The most likely scenario in which OligoPVP can be used successfully is to generate hypotheses 
for combinations of specific variants after other variant prioritization approaches have failed to yield significant 
results. Alternatively, knowledge of family history or ethnic background might suggest the contribution of two or 
more genes to the disease phenotype, and OligoPVP can then be used to identify plausible combinations of genes 
and allelic variants.
www.nature.com/scientificreports/
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OligoPVP is, to the best of our knowledge, the first phenotype-based method to identify disease modules 
in personal genomic data. With the large (i.e., exponential) number of combinations of variants that have to be 
evaluated in finding disease modules, it is clear that any computational method has to make use of background 
knowledge to restrict the search space of potentially causative combinations of variants. OligoPVP is such a 
method which uses knowledge about interactions and phenotype associations to limit the search space. In the 
future, more background knowledge can be incorporated to improve OligoPVP’s coverage as well as accuracy. 
OligoPVP is freely available at https://github.com/bio-ontology-research-group/phenomenet-vp.
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